← All Progyny, INC filings

Progyny, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PGNY
Progyny, INC
10-K: Progyny Reports Strong 2025 Growth, Expands Health Solutions
Progyny, Inc. announced a 10% revenue increase to $1.29 billion in 2025, driven by expanded fertility and family building solutions and a growing client base, alongside a new $200 million share repurchase program.
NASDAQ
PGNY
Progyny, INC
10-K: Progyny, Inc. Reports Solid Growth in 2024, Navigates Client Loss and Sets Course for Future Expansion
Progyny, Inc.'s 2024 10-K filing reveals a year of revenue growth, strategic acquisitions, and ongoing efforts to manage risks and expand its market presence despite the loss of a major client.
NASDAQ
PGNY
Progyny, INC
10-K: Progyny, Inc. Outlines Capital Structure and Shareholder Rights in 10-K Filing
Progyny, Inc.'s 10-K filing details the company's capital structure, voting rights, and anti-takeover provisions as of December 31, 2023.